Ethan Rowin to Death, Sudden, Cardiac
This is a "connection" page, showing publications Ethan Rowin has written about Death, Sudden, Cardiac.
Connection Strength
5.413
-
Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
Score: 0.524
-
Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.
Score: 0.512
-
Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
Score: 0.437
-
Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
Score: 0.426
-
Chan RH, van der Wal L, Liberato G, Rowin E, Soslow J, Maskatia S, Chan S, Shah A, Fogel M, Hernandez L, Anwar S, Voges I, Carlsson M, Buddhe S, Laser KT, Greil G, Valsangiacomo-Buechel E, Olivotto I, Wong D, Wolf C, Grotenhuis H, Rickers C, Hor K, Rutz T, Kutty S, Samyn M, Johnson T, Hasbani K, Moore JP, Sieverding L, Detterich J, Parra R, Chungsomprasong P, Toro-Salazar O, Roest AAW, Dittrich S, Brun H, Spinner J, Lai W, Dyer A, Jablonowsk R, Meierhofer C, Gabbert D, Prsa M, Patel JK, Hornung A, Diab SG, House AV, Rakowski H, Benson L, Maron MS, Grosse-Wortmann L. Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic Cardiomyopathy: A Multicenter Cohort Study. JAMA Cardiol. 2024 Nov 01; 9(11):1001-1008.
Score: 0.174
-
Maron MS, Rowin EJ, Maron BJ. Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes". Circulation. 2024 Sep 17; 150(12):e255-e256.
Score: 0.173
-
Carrick RT, Ahamed H, Sung E, Maron MS, Madias C, Avula V, Studley R, Bao C, Bokhari N, Quintana E, Rajesh-Kannan R, Maron BJ, Wu KC, Rowin EJ. Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approach. Heart Rhythm. 2024 08; 21(8):1390-1397.
Score: 0.165
-
Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
Score: 0.143
-
Sridharan A, Maron MS, Carrick RT, Madias CA, Huang D, Cooper C, Drummond J, Maron BJ, Rowin EJ. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2022 01; 33(1):20-29.
Score: 0.143
-
Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
Score: 0.134
-
Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
Score: 0.133
-
Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
Score: 0.130
-
Maron MS, Brush J, Rowin EJ, Maron BJ. Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm. 2021 01; 18(1):148-150.
Score: 0.130
-
Maron BJ, Mackey-Bojack S, Facile E, Duncanson E, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. Am J Cardiol. 2020 07 15; 127:139-141.
Score: 0.128
-
Maron BJ, Rowin EJ, Maron MS. Concerns About the HCM Risk-Kids Study. JAMA Cardiol. 2020 03 01; 5(3):362-363.
Score: 0.126
-
Maron M, Rowin E, Maron BJ. Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy. Heart. 2019 12; 105(24):1850-1851.
Score: 0.122
-
Maron BJ, Rowin EJ, Maron MS. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circ Res. 2019 08 02; 125(4):370-378.
Score: 0.121
-
Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
Score: 0.121
-
Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
Score: 0.111
-
Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
Score: 0.103
-
Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. J Am Heart Assoc. 2016 Feb 12; 5(2).
Score: 0.095
-
Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016 Feb 01; 117(3):434-5.
Score: 0.094
-
Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
Score: 0.091
-
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 05; 130(6):484-95.
Score: 0.086
-
Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
Score: 0.077
-
Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
Score: 0.074
-
Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
Score: 0.042
-
Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 02 01; 212S:S64-S76.
Score: 0.041
-
Maron BJ, Rowin EJ, Maron MS. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Am J Cardiol. 2024 02 01; 212S:S77-S82.
Score: 0.041
-
Maron MS, Mitten M, Borchers J, Rowin EJ, Maron BJ. Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease. J Am Coll Cardiol. 2023 08 29; 82(9):828-832.
Score: 0.040
-
Maron BJ, Estes NAM, Rowin EJ, Maron MS, Reynolds MR. Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2023 07 25; 82(4):353-373.
Score: 0.040
-
Maron MS, Rowin EJ, Bonaventura J, Maron BJ. Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field? Am J Cardiol. 2023 08 01; 200:236-238.
Score: 0.040
-
Fahmy AS, Rowin EJ, Jaafar N, Chan RH, Rodriguez J, Nakamori S, Ngo LH, Pradella S, Zocchi C, Olivotto I, Manning WJ, Maron M, Nezafat R. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value?of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2024 01; 17(1):16-27.
Score: 0.040
-
Wang RS, Rowin EJ, Maron BJ, Maron MS, Maron BA. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Cardiovasc Res. 2023 05 02; 119(3):e125-e127.
Score: 0.039
-
Maron MS, Rowin E, Spirito P, Maron BJ. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023 03 27; 109(8):589-594.
Score: 0.039
-
Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players. Am J Med. 2023 03; 136(3):315-321.
Score: 0.038
-
Abdelfattah OM, Martinez M, Sayed A, ElRefaei M, Abushouk AI, Hassan A, Masri A, Winters SL, Kapadia SR, Maron BJ, Rowin E, Maron MS. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2022 11; 8(11):1417-1427.
Score: 0.038
-
Butzner M, Sarocco P, Maron MS, Rowin E, Teng CC, Stanek E, Tan H, Robertson LA. Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. Am J Cardiol. 2022 07 01; 174:120-125.
Score: 0.037
-
Maron BJ, Rowin EJ, Madias C, Dolan N, Maron MS. Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). Am J Cardiol. 2022 04 01; 168:163-165.
Score: 0.036
-
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):390-414.
Score: 0.036
-
Papanastasiou CA, Zegkos T, Karamitsos TD, Rowin EJ, Maron MS, Parcharidou D, Kokkinidis DG, Karvounis H, Rimoldi O, Maron BJ, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021 06 01; 332:127-132.
Score: 0.034
-
Chinedozi I, Zarin J, Quinn R, Rowin E, Cobey FC, Trzcinka A. Two Tales of Cardiomyopathy: Underscore for One Health Initiative. J Cardiothorac Vasc Anesth. 2021 09; 35(9):2811-2814.
Score: 0.034
-
Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
Score: 0.033
-
Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2020 08; 6(8):1019-1021.
Score: 0.032
-
Maron MS, Rowin EJ, Maron BJ. Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy? Trends Cardiovasc Med. 2021 01; 31(1):32-33.
Score: 0.031
-
Ghiselli L, Marchi A, Fumagalli C, Maurizi N, Oddo A, Pieri F, Girolami F, Rowin E, Mazzarotto F, Cicoira M, Ribichini F, Arretini A, Targetti M, Passantino S, Cecchi F, Marchionni N, Maron M, Mori F, Olivotto I. Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2020 11; 27(17):1821-1831.
Score: 0.031
-
Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):376-378.
Score: 0.028
-
Maron MS, Rowin EJ, Maron BJ. How to Image Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 07; 10(7).
Score: 0.026
-
Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
Score: 0.023
-
Kim J, Parikh P, Mahboob M, Arrighi JA, Atalay MK, Rowin EJ, Maron MS. Asymptomatic young man with Danon disease. Tex Heart Inst J. 2014 Jun; 41(3):332-4.
Score: 0.021